搜索
Nektar Therapeutics
NKTR添加自选
70.620USD
-3.710-4.99%
收盘 05/15, 16:00（美东）报价延迟15分钟
2.39B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.99%
5天
-13.76%
1月
-15.14%
6月
+24.59%
今年开始到现在
+67.03%
1年
+592.35%
TradingKey Nektar Therapeutics股票评分
单位: USD 更新时间: 2026-05-15操作建议
Nektar Therapeutics当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名90/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价153.25。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nektar Therapeutics评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Nektar Therapeutics亮点
亮点风险
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
业绩增长期
公司处于发展阶段，最新年度总收入55.23M美元
估值低估
公司最新PE估值-8.91，处于3年历史低位
机构加仓
最新机构持股20.71M股，环比增加6.00%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值4.00K
活跃度增加
近期活跃度增加，过去20天平均换手率1.38
分析师目标
根据
10
位分析师
买入
评级
153.250
目标均价
+101.78%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Nektar Therapeutics新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nektar Therapeutics简介
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
公司代码NKTR
公司Nektar Therapeutics
CEORobin (Howard W)
网址https://www.nektar.com/
相关品种
